Michael Artinger, PhD

Michael Artinger, PhD
Michael Artinger, PhD, Executive Vice President and Managing Director VIC Colorado Branch, has spent his career transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep domain expertise across multiple verticals, including therapeutics, vaccines, medical devices, diagnostics and information technology/software. Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.
Find me on:

Recent Posts

The Accelerating Pace of Life Science Innovation in a (Soon-to-Be) Post-Pandemic World

As discussed in my previous article “Portfolio Diversification During Times of Market Volatility,”[1] one of the few positive outcomes of the worldwide pandemic is the increasing recognition of the power of innovation...

Inside The VIC Fellows Program

VIC Technology Venture Development’s (www.victech.com) investment model sources promising life science innovation directly from universities across the nation, allocating funding to form startup companies and advance...

Portfolio Diversification in Times of Market Volatility

Update It is now March 2021, and nine months after writing this piece below, saying that things have evolved would be an understatement. Focusing on the positive progress made to date, we have three approved vaccines in...

The Emerging Remote Workplace: Digital Best Practices for Investor Groups

As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...

White Paper: New Paradigms of Life Science Investing

For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation.  Anyone doing...

White Paper: Accessing Innovation Directly From The Source - The Growing Trend Of Venture Capital Company Formation

Historically, innovative technologies discovered at universities, institutes and national labs have had two primary paths towards commercialization: (1) licensing to a large, pre-existing company; or, (2) licensing to...

FEATURED RESOURCES

News
Akeso Biomedical Announces European Food Safety Authority Positive Scientific Opinion
White Paper
Portfolio Diversification in Times of Market Volatility
Case Study
The Accelerating Pace of Life Science Innovation in a (Soon-to-Be) Post-Pandemic World
Updates
VIC 2020 Annual Report Executive Summary
News
CardioWise Receives US FDA 510(k) Clearance for Heart Function Analysis Software
Case Study
Opportunity Assessment: How To Vet So Much Tech
Interview
Inside CU Innovations: An Interview with Executive Director, Kim Muller
White Paper
Accessing Innovation Directly from the Source - Growing Trends in Venture Capital Company Formation
Updates
VIC Technology Venture Development Announces New Board of Directors Appointment
News
VIC Portfolio Company, BlueInGreen, Acquired by Chart Industries
Interview
VIC Fellows Spotlight: Travis Nemkov, PhD
From The Corner Office
Vixiar: Solving a Big Problem With a Small Device